Five things for pharma marketers to know: Friday, August 11, 2017

Share this content:

1. Egalet said it will cut 40% of its workforce, telling investors it plans to devote more resources to educating providers about its abuse-deterrent version of morphine, Arymo ER. The FDA approved Armyo ER in January. (BioPharmaDive)

2. Novo Nordisk executives have set high expectations for experimental weight-loss drug semaglutide. In a Phase-II trial, patients taking the drug lost an average of 39 pounds, which they said is a “new efficacy standard for anti-obesity medicines.” (Endpoints News)

3. President Trump declared the opioid epidemic a national emergency. That declaration will give states and federal agencies like the Centers for Disease Control and Prevention more resources to fight the crisis. (CNN)

4. A survey of 148 large companies said they expect the cost of employer healthcare plans to grow 5% next year. The companies attributed the increase to expensive specialty medicines as well as members with high medical costs. (WaPo)

5. More than one-third of insured cancer patients spend more out of pocket than they planned to, according to a survey conducted by Duke University and published in JAMA Oncology. (Forbes)

Share this content:
Scroll down to see the next article